NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS
Go back to NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS| Amgen Inc (NASDAQ: AMGN) | Delayed: 393.16 +7.51 (1.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $385.65 | 52 Week High | $176.85 | |||
| Open | $385.71 | 52 Week Low | $133.64 | |||
| Day High | $394.50 | P/E | 59.21 | |||
| Day Low | $381.90 | EPS | $6.64 | |||
| Volume | 2,830,379 | |||||
